<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> (T2DM) is a multifaceted disease, characterized by <z:e sem="disease" ids="C0020456" disease_type="Disease or Syndrome" abbrv="">hyperglycaemia</z:e>, resulting from a combination of <z:hpo ids='HP_0000855'>insulin resistance</z:hpo>, impaired incretin action and Î²-cell dysfunction leading to relative insulin deficiency </plain></SENT>
<SENT sid="1" pm="."><plain>Although traditional anti-<z:mp ids='MP_0002055'>diabetes</z:mp> agents improve <z:e sem="disease" ids="C0020456" disease_type="Disease or Syndrome" abbrv="">hyperglycaemia</z:e>, they do so at a cost, which may entail <z:hpo ids='HP_0001943'>hypoglycemia</z:hpo> and <z:hpo ids='HP_0004324'>increased body weight</z:hpo>; exacerbating <z:e sem="disease" ids="C0242339" disease_type="Disease or Syndrome" abbrv="">dyslipidemia</z:e>, <z:hpo ids='HP_0000822'>hypertension</z:hpo> and components of <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> and <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> associated with T2DM-potentially increasing cardiovascular risk </plain></SENT>
<SENT sid="2" pm="."><plain>At diagnosis, many patients with T2DM are treated with medical nutritional therapy (MNT) and exercise, then single or multiple oral anti-<z:mp ids='MP_0002055'>diabetes</z:mp> agents until treatment failure, when insulin is used </plain></SENT>
<SENT sid="3" pm="."><plain>This strategy has been challenged by recommendations for polypharmacy approaches to the treatment of T2DM, as current strategies are unable to improve multiple aspects of the disease, nor are they likely to address underlying pathophysiology </plain></SENT>
<SENT sid="4" pm="."><plain>Although the 2009 American <z:mp ids='MP_0002055'>Diabetes</z:mp> Association (<z:chebi fb="36" ids="39048">ADA</z:chebi>) and the European Association for the Study of <z:mp ids='MP_0002055'>Diabetes</z:mp> (EASD) treatment algorithm recommends a stepwise approach with MNT and <z:chebi fb="0" ids="6801">metformin</z:chebi>, later adding oral agents, incretin-based therapies or insulin, some experts have recommended a more aggressive approach </plain></SENT>
<SENT sid="5" pm="."><plain>In his 2008 ADA Banting Lecture, Dr. Ralph DeFronzo recommended early treatment with <z:chebi fb="0" ids="6801">metformin</z:chebi>, TZD and exenatide at initiation of therapy </plain></SENT>
<SENT sid="6" pm="."><plain>The authors' of this article recommend an aggressive early polypharmacy approach addressing underlying pathophysiology, including the incretin defect-with MNT and exercise, <z:chebi fb="0" ids="6801">metformin</z:chebi> and an incretin-based therapy and/or basal insulin if glycemic goal is not achieved within 3 months </plain></SENT>
<SENT sid="7" pm="."><plain>This approach attempts to modify the disease, aiming for tight glycemic control, <z:hpo ids='HP_0001824'>weight loss</z:hpo>, reduced <z:hpo ids='HP_0001943'>hypoglycemia</z:hpo>, improvements to <z:hpo ids='HP_0000822'>hypertension</z:hpo>, <z:e sem="disease" ids="C0242339" disease_type="Disease or Syndrome" abbrv="">dyslipidemia</z:e> and <z:hpo ids='HP_0000855'>insulin resistance</z:hpo>-and improved cardiovascular outcomes </plain></SENT>
</text></document>